Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Shareholder Meeting (May 2026)
23 slides from Neuren Pharmaceuticals's shareholder meeting presentation, May 27, 2026
Slide 1: Chairman's Address at 2026 Annual Meeting of Shareholders
Neuren (NEU) – ASX Announcement 27 May 2026 Chairman’s Address at 2026 Annual Meeting of Shareholders Our purpose at Neuren remains unchanged. We are focused on developing medicines for children suffering from rare and serious neurological disabilities that have no, or very limited, treatment options
Slide 2: Chairman's Address (continued)
The broader rollout of DAYBUE STIX began in early April 2026 and we look forward to monitoring its impact in the coming quarters. We believe that there remains meaningful growth potential in the United States, with penetration rates currently around 60% at Centres of Excellence and approximately 28%
Slide 3: Chairman's Address: capital management and buyback
Two months ago, we announced and commenced another share buyback program given our view that the Company’s valuation falls well short of the strength of our assets and outlook. This is based on our own models and those of the eight broker research analysts who formally cover Neuren. We are currently
Slide 4: Annual Shareholders' Meeting CEO presentation May 2026
For personal use only Annual Shareholders’ Meeting CEO presentation 27 May 2026 IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES
Slide 5: Forward looking statements
Forward looking statements This presentation contains forward looking statements that involve For personal use only risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expe
Slide 6: Large potential upside for shareholders is enabled by financial strength
Large potential upside for shareholders is enabled by financial strength Long-term income growth NNZ-2591 indications prioritised for from DAYBUE ® For personal use only maximum commercial impact (trofinetide) Phelan-McDermid syndrome A$293 million cash as at 31 Mar Hypoxic Ischemic Pitt Hopkins syn
Slide 7: Economics to Neuren from Acadia partnership
Economics to Neuren from Acadia partnership North America Outside North America For personal use only US$10m upfront in 2018 US$100m upfront in 2023 US$10m in 2022 following acceptance of NDA for review US$35m following 1st commercial sale in Europe US$40m in 2023 following 1st commercial sa
Slide 8: Strong DAYBUE sales momentum
Strong DAYBUE sales momentum Q1 2026 saw the highest y-o-y growth since 3Q 2024 For personal use only DAYBUE Net Sales (US$m) Royalty to Neuren (US$m) +18–25% + 19–27% 490 391 460 54 348 42 50 37 DAYBUE STIX US launch: 177 18 • limited basis in COEs1 Q1 Q1 Q1 2026 +20% +23% 85 101 8.5 10.4 • broadly
Slide 9: DAYBUE STIX: a new formulation based on Rett community feedback
DAYBUE STIX: a new formulation based on Rett community feedback Powder for oral solution approved by US FDA in December 2025 For personal use only Differentiated features Incremental demand potential Mixes easily into beverages Provides an additional lever to Customizable volume engage both naïve (n
Slide 10: Significant upside in the US
Significant upside in the US Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome1 For personal use only Current US Penetration Rate2 Current Persistency Rate DAYBUE STIX COEs Outside COEs (before DAYBUE STIX) 100% 250 pre
Slide 11: Neuren is leading the development of a first treatment for Phelan-McDermid syndrome
Neuren is leading the development of a first treatment for Phelan- McDermid syndrome (PMS) The Voice of the Patient…..1 For personal use only “PMS has an overwhelming unmet medical need. There are no FDA approved treatments for PMS despite its severely debilitating manifestations. Parents and caregi
Slide 12: Koala - the first ever Phase 3 trial in PMS
Koala - the first ever Phase 3 trial in PMS Alignment with FDA on single Phase 3 trial design and endpoints to support a NDA For personal use only Same age range (3-12) and same length of treatment (13 weeks) as Phase 2 Up to 4 weeks Double-blind, 13 weeks Open label, 12 months Target dosing equival
Slide 13: Key Phase 2 endpoints robustly positive in PMS trial
Key Phase 3 endpoints robustly positive in Phase 2 trial Co-primary Endpoints in Phase 2 Results1 For personal use only Phelan-McDermid Syndrome Assessment of 16/18 subjects showed improvement Change (PMSA-C), previously referred to as Mean score: 2.4 CGI-I in Phase 2 (P < 0.00012) 16/18 subjects sh
Slide 14: Koala study progress as of May 2026
Koala study progress as of 27 May 2026 Koala study site map in US and Canada For personal use only 9 patients randomised (2 completed), all at first 2 sites 7 sites activated, 14 to activate soon >80 families referred to sites CTA approval received for sites in Canada Open-label extension study Acti
Slide 15: Next steps for NNZ-2591 in HIE and PTHS
Next steps for NNZ-2591 in HIE and PTHS HIE PTHS • PTHS-specific clinical global impression For personal use only • Generally accepted Neuren’s IND-opening proposal and the doses to be evaluated (CGI) scale may be used as a co-primary FDA endpoint if it is accompanied by an FDA • Guidance on the inc
Slide 16: Substantial market opportunities in PMS, PTHS and HIE
Substantial market opportunities in PMS, PTHS and HIE Potential patients For personal use only Disorder Published prevalence estimates US Europe Japan PMS 1/8,000 to 1/15,000 males and females1 19,000 - 21,000 - 5,000 - 9,0004 36,0004 41,0004 ~1% of autism patients have SHANK3 mutations PTHS 1/34,00
Slide 17: Highly experienced leadership team with strong track record of execution
Highly experienced leadership team with strong track record of execution Liza Squires, MD Larry Glass, BA Daryl Dekarske, MPH For personal use only Chief Medical Officer Chief Science Officer Chief Regulatory Officer Board-certified pediatric neurologist 30+ years of experience in the life 30+ years
Slide 18: A uniquely positioned ASX biotech company
A uniquely positioned ASX biotech company For personal use only Sustainable growing royalty Recurring royalty supplemented NNZ-2591 value potential to be income from DAYBUE, driven by by significant milestone unlocked through successful strong momentum in US and payments, next US$50m payment executi
Slide 19: Contact
For personal use only CONTACT investorrelations@neurenpharma.com 16
Slide 20: Proxy votes: Resolution 1 Re-election of Director Joe Basile
Resolutions Proxy Votes Received For personal use only Lodged For Lodged Open Lodged Against Total % Resolution 1 Available issued Votes % Votes % Votes % Votes capital RE-ELECTION OF DIRECTOR - JOE 53,645,115 92.46 71,060 0.12 4,305,931 7.42 58,022,106 45.93 BASILE 1
Slide 21: Proxy votes: Resolution 2 Auditor remuneration
Resolutions Proxy Votes Received For personal use only Lodged For Lodged Open Lodged Against Total % Resolution 2 Available issued Votes % Votes % Votes % Votes capital AUDITOR REMUNERATION 57,715,017 99.48 70,931 0.12 228,630 0.39 58,014,578 45.93 2
Slide 22: Proxy votes: Resolution 3 Issue of options to Jon Pilcher
Resolutions Proxy Votes Received For personal use only Lodged For Lodged Open Lodged Against Total % Resolution 3 Available issued Votes % Votes % Votes % Votes capital ISSUE OF OPTIONS TO MANAGING 48,788,280 86.42 70,260 0.12 7,599,324 13.46 56,457,864 44.69 DIRECTOR – JON PILCHER 3
Slide 23: Proxy votes: Resolution 4 Amendments to the Constitution
Resolutions Proxy Votes Received For personal use only Lodged For Lodged Open Lodged Against Total % Resolution 4 Available issued Votes % Votes % Votes % Votes capital AMENDMENTS TO THE COMPANY’S 41,215,748 71.04 73,797 0.13 16,725,242 28.83 58,014,787 45.93 CONSTITUTION 4
Neuren Pharmaceuticals — Shareholder Meeting (May 2026) on 6ix